Assessment of levetiracetam and valproic acid as monotherapy for quality of life in partial epilepsy patients
DOI:
https://doi.org/10.18203/2319-2003.ijbcp20194779Keywords:
Partial epilepsy, Quality of life, QOLIE-10, Levetiracetam, Valproic acidAbstract
Background: Quality of life (QOL) is important in patients of epilepsy as it is affected both by disease as well as therapy. QOL is the most overlooked component of antiepileptic treatment.
Methods: An observational analytical study was conducted in the Department of Pharmacology in collaboration with Department of Neurology of Himalayan Institute of Medical Science, Dehradun over 12 months. 80 patients satisfying inclusion criteria were enrolled and divided into two groups based on physician discretion and followed up for 12 weeks. Patients were evaluated at 0 and 12 weeks for quality of life using QOLIE-10 self-administered questionnaire, they were also assessed for seizure control and drug related adverse effects.
Results: 60 patients were enrolled and divided into two treatment groups as per physician discretion, levetiracetam (30) and valproic acid (30) groups. Study groups showed significant improvement in QOL (mean change in QOL17.95±2.527 for LEV and 11.56±3.540 for VPA). Levetiracetam (LEV) group showed significant improvement over valproic acid (VPA) group (p=0.05) at 12 weeks. Patients who achieved total seizure control at 6 weeks were 93.33% patients in levetiracetam and 90% in valproic acid group, reason being non adherence which was 6.67% and 10% respectively. Adverse event recorded with levetiracetam (03), most common being drowsiness and with valproic acid (08), with most common being anorexia.
Conclusions: Levetiracetam therapy has led to better quality of life and has the same seizure control as valproic acid, and has shown to have lower incidence of adverse effect.
Metrics
References
Tatum WO IV, Benbadis S, Vale FL. The neurosurgical treatment of epilepsy. Arch Fam Med. 2000;9:1142-6.
Banerjee TK, Ray BK, Das SK, Hazra A, Ghosal MK, Chaudhuri A, et al. A longitudinal study of epilepsy in Kolkata, India. Epilepsia. 2010;51:2384-91.
Nelson LP, Savelli-Castillo I. New antiepileptic agents. Pediatr Dent. 2004;26:58-62.
Kaminow L, Schimschock JR, Hammer AE, Vuong A. Lamotrigine monotherapy compared with carbamazepine, phenytoin, or valproate monotherapy in patients with epilepsy. Epilepsy Behav. 2003;4:659-66.
Viteri C, Codina M, Cobaleda S, Lahuerta J, Barriga J, Morales MD. Quality of life in Spanish epilepsy patients on monotherapy with Lamotrigine or Valproic acid. Seizure. 2010;19:432-8.
Cramer JA, Perrine K, Devinsky O, Meador K. A brief questionnaire to screen for quality of life in epilepsy: the QOLIE-10. Epilepsia. 1996;37(6):577-82.
Norsa’adah B, Zainab J, Knight A. The quality of life of people with epilepsy at a tertiary referral centre in Malaysia. Health and Quality of life Outcomes. 2013;11:143-8.
Shanmukhi S, Sita Jayalakshmi S, Anand B. Factors associated with quality of life in adult epilepsy patients-a hospital based study from south India. Res Neurol Int. 2015;1-5.
Jacoby A. Epilepsy and the quality of everyday life: findings from a study of people with well-controlled epilepsy. Soc Sci Med. 1992;34:657-66.
Cramer JA, Perrine K, Devinsky O, Meador K. A brief questionnaire to screen for quality of life in epilepsy: the QOLIE-10. Epilepsia. 1996;37(6):577-82.
Suresh S, Chakraborty A, Virupakshaiah A, Kumar N. Efficacy and safety of levetiracetam and carbamazepine as monotherapy in partial seizures. Epilepsy Res Treat. 2015;2015:415082.
Marson A, Al-Kharusi A, Alwaidh M, Appleton R, Baker G, Chadwick D, et al. The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. Lancet. 2007;369(9566):1016-26.
Tatum WO IV, Benbadis S, Vale FL. The neurosurgical treatment of epilepsy. Arch Fam Med. 2000;9:1142-6.
Schmidt D. Efficacy of new antiepileptic drugs. Epilepsy Curr. 2011;11:9-11.
Ahmad N, Othaman NI, Islahudin F. Medication adherence and quality of life in epilepsy patients. Int J Pharm Pharm Sci. 2013;5(2):401-4.
Roopa BS, Narayan SS, Sharma G, Rodrigues RJ, Kulkarni C. Pattern of adverse drug reactions to anti-epileptic drugs: a cross-sectional one-year survey at a tertiary care hospital. Pharmacoepidemiol Drug Safety. 2008;17(8):807-12.
Das K, Bannerjee M, Mondal GP, Devi LG, Singh OP, Mukherjee BB. Evaluation of socio-economic factors causing discontinuation of epilepsy treatment resulting in seizure recurrence: a study in urban epilepsy clinic. Seizure. 2007;16(7):601-7.
